Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study

Abstract Background The impact of hepatic steatosis (HS) on treatment response following nucleos(t)ide analogue (NA) treatment for chronic hepatitis B (CHB) patients has not been clearly elucidated. We aimed to investigate the difference in HBeAg seroclearance between NA-treated HBeAg-positive CHB p...

Full description

Bibliographic Details
Main Authors:	Yi-Cheng Chen, Wen-Juei Jeng, Chao-Wei Hsu, Chun-Yen Lin
Format:	Article
Language:	English
Published:	BMC 2020-05-01
Series:	BMC Gastroenterology
Subjects:	Chronic hepatitis B Hepatic steatosis HBeAg seroclearance Nucleos(t)ide analogue treatment
Online Access:	http://link.springer.com/article/10.1186/s12876-020-01289-w

Similar Items

What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?
by: Kadir Demir, et al.
Published: (2007-04-01)

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice
by: Mingfan Geng, et al.
Published: (2017-09-01)

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
by: Xiaomei Wang, et al.
Published: (2020-10-01)

Study of hepatic histomorphology in HBeAg+ and HBeAg− patients with CHB: Experience from Bangladesh
by: Ayub Al Mamun, et al.
Published: (2013-01-01)

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
by: Flamir da Silva Victoria, et al.

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
by: Weiqiang Gan, et al.
Published: (2020-12-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients
by: Yu Cui, et al.
Published: (2019-06-01)

The Relationship between Intrahepatic Distribution of Hepatitis B Virus Core Antigen and Serum ALT, HBV DNA Levels and HBeAg Status
by: He Qing, et al.
Published: (2012-06-01)

¿A quién tratar?
by: Marianella Madrigal-Borloz
Published: (2008-11-01)

The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions
by: Ott Jördis J, et al.
Published: (2012-06-01)

Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus
by: Anna Kramvis, et al.
Published: (2018-10-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
by: Ruochan Chen, et al.
Published: (2021-07-01)

Comparison of evolutionary patterns of different HBeAg status in HBV genotype B and C
by: Cai Ying, et al.
Published: (2015-12-01)

Quantitative HBsAg and Qualitative HBeAg Predicts Intrauterine Placental Infection and Umbilical Blood Cord in Pregnant Women
by: Erry Gumilar Dachlan, et al.
Published: (2020-10-01)

Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion
by: Stijn Van Hees, et al.
Published: (2019-07-01)

Soroconversão tardia do HBeAg em portadores do subgenótipo D4 do vírus da hepatite B
by: Souza, Marinilde Teles
Published: (2017)

Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters
by: Su-Ru Lin, et al.
Published: (2021-06-01)

Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment
by: Jiezuan Yang, et al.
Published: (2020-07-01)

Hepatitis B and NAFLD: Lives Crossed
by: María Luisa Morales,, et al.
Published: (2017-03-01)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
by: Hui Ma, et al.
Published: (2016-01-01)

A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon
by: Kfutwah Anfumbom KW, et al.
Published: (2012-03-01)

Naturally Occurring Mutations within HBV Surface Promoter II Sequences Affect Transcription Activity, HBsAg and HBV DNA Levels in HBeAg-Positive Chronic Hepatitis B Patients
by: Ran Hao, et al.
Published: (2019-01-01)

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
by: E K Ibragimov, et al.
Published: (2019-02-01)

Response of Preterm Infants of Mothers Who Are Chronic Carriers of Both HBsAg and HBeAg to Pre-52 Containing Hepatitis 8 Vaccine (TGP 943) - A Preliminary Report
by: Abdul Hamid Sutohardjo
Published: (2018-10-01)

Status of Hepatitis Be Antigen in Chronic Hepatitis B Patients from Various Regions of Pakistan
by: Agha Babar Hussain
Published: (2017-09-01)

HBeAg-negative chronic hepatitis
by: M M Ibragimova, et al.
Published: (2004-02-01)

Combination of Peginterferon α-2b (12 kDa) and Lamivudine in difficult-to-treat chronic hepatitis B-an Indian experience
by: Deepak N. Amarapurkar, et al.
Published: (2005-01-01)

Response predictors to treatment with pegylated interferon in chronic hepatitis B
by: Paulo Roberto Abrão Ferreira, et al.

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis
by: Wei Wei, et al.
Published: (2015-08-01)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
Published: (2006-01-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

HBV Hepatitis and Related Renal Nephropathies: Pathogenesis and Treatment
by: Maurizio Salvadori, et al.
Published: (2020-11-01)

Frequency of HBsAg in pregnant women in Gorgan, Iran
by: Cheraghali F (MD), et al.
Published: (2012-01-01)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01)

Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance
by: Hyun Woong Lee, et al.
Published: (2020-04-01)

Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog
by: Ji X, et al.
Published: (2020-06-01)